Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities
British Journal of Pharmacology, ISSN: 1476-5381, Vol: 176, Issue: 18, Page: 3489-3507
2019
- 319Citations
- 348Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations319
- Citation Indexes319
- 319
- CrossRef234
- Captures348
- Readers348
- 348
- Mentions2
- Blog Mentions1
- 1
- News Mentions1
- 1
Most Recent Blog
A mutation causing alcohol-related ‘Asian glow’ may have ties to Alzheimer’s disease
If I drink even a few sips of alcohol, in minutes my face becomes tomato red. I, and another 560 million people, have a mutation in the aldehyde dehydrogenase 2 gene, ALDH2, that greatly reduces the activity of the enzyme coded by this gene. To put it plainly, we can't completely break down alcohol. Instead, we build up a toxic intermediate, acetaldehyde, that causes flushing and inflammation. Thi
Most Recent News
Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.
Br J Pharmacol. 2019 Jan 24; Authors: Perez Ortiz JM, Swerdlow RH PubMed: 30675901 Submit Comment
Review Description
Dysfunction of cell bioenergetics is a common feature of neurodegenerative diseases, the most common of which is Alzheimer's disease (AD). Disrupted energy utilization implicates mitochondria at its nexus. This review summarizes some of the evidence that points to faulty mitochondrial function in AD and highlights past and current therapeutic development efforts. Classical neuropathological hallmarks of disease (β-amyloid and τ) and sporadic AD risk genes (APOE) may trigger mitochondrial disturbance, yet mitochondrial dysfunction may incite pathology. Preclinical and clinical efforts have overwhelmingly centred on the amyloid pathway, but clinical trials have yet to reveal clear-cut benefits. AD therapies aimed at mitochondrial dysfunction are few and concentrate on reversing oxidative stress and cell death pathways. Novel research efforts aimed at boosting mitochondrial and bioenergetic function offer an alternative treatment strategy. Enhancing cell bioenergetics in preclinical models may yield widespread favourable effects that could benefit persons with AD. Linked Articles: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Bibliographic Details
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know